Bron : The daily Quint
THE STIFEL NICOLAUS BEGINS COVERAGE ON GALAPAGOS NV (GLPG)
February 19, 2017 Susan G. Crespo
The Stifel Nicolaus Begins Coverage on Galapagos NV (GLPG)
Stifel Nicolaus began coverage on shares of Galapagos NV (NASDAQ:GLPG) in a research report released on Thursday morning. The brokerage issued a hold rating and a $65.00 price objective on the stock.
A number of other analysts have also commented on GLPG. Cowen and Company reaffirmed a buy rating on shares of Galapagos NV in a research note on Sunday, October 30th. TheStreet lowered Galapagos NV from a hold rating to a sell rating in a research note on Wednesday, November 30th. Zacks Investment Research raised Galapagos NV from a hold rating to a buy rating and set a $66.00 price objective on the stock in a research note on Wednesday, November 2nd. Finally, Goldman Sachs Group, Inc. (The) raised Galapagos NV from a neutral rating to a buy rating in a research note on Tuesday, October 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Galapagos NV currently has a consensus rating of Hold and a consensus price target of $66.40.
Shares of Galapagos NV (NASDAQ:GLPG) traded down 0.26% during trading on Thursday, hitting $68.54. The stock had a trading volume of 15,058 shares. Galapagos NV has a one year low of $37.03 and a one year high of $73.37. The company’s market cap is $3170.39 billion. The stock’s 50-day moving average price is $61.05 and its 200-day moving average price is $58.80.
A number of institutional investors have recently added to or reduced their stakes in the company. Advisors Preferred LLC acquired a new position in Galapagos NV during the third quarter valued at $131,000. Susquehanna International Group LLP acquired a new position in Galapagos NV during the third quarter valued at $222,000. Fiera Capital Corp acquired a new position in Galapagos NV during the second quarter valued at $302,000. Citadel Advisors LLC acquired a new position in Galapagos NV during the second quarter valued at $347,000. Finally, BlackRock Institutional Trust Company N.A. acquired a new position in Galapagos NV during the third quarter valued at $569,000. Hedge funds and other institutional investors own 21.05% of the company’s stock.
Galapagos NV Company Profile
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos’ most advanced novel mode-of-action program, was discovered using the Company’s proprietary target discovery technology, and is being developed by us in Phase 3 in rheumatoid arthritis. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas.
@ tuinman (staat onderaan app !)